Sosei Heptares is a highly respected partner-of-choice, having signed deals with world-leading pharmaceutical and biotechnology companies, which have significant franchises in key therapeutic areas. Our partners validate our technologies, balance our risk and provide us with a broad source of non-dilutive capital, which we invest in the development of our GPCR pipeline.
Our strategic partnerships range from clinical development collaborations, joint discovery and co-development to licensing and royalty arrangements. Through these collaborations, aimed at discovering, developing and commercializing our products, we intend to continue to access technological, financial, marketing, manufacturing and other resources of our partners.
Our Business Development
Sosei Heptares is leveraging its transformational StaR® technology and SBDD platform to generate a broad and deep pipeline of first-in-class and best-in-class GPCR-targeted medicines. We are focused on designing and advancing novel drug candidates with high levels of validation, including small molecules, peptides and antibodies, across multiple areas of disease.
The scope of the opportunity using our approach extends well beyond our growing in-house pipeline. Large and untapped regions of the GPCR target universe, previously regarded as undruggable, are now tractable for rational drug discovery using our StaR® technology and SBDD platform.
We welcome interest from pharmaceutical and biotechnology companies seeking access to this broader GPCR target landscape through collaboration.
For more information on out-licensing or partnering opportunities, please contact: